Source:http://linkedlifedata.com/resource/pubmed/id/19584739
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2009-8-11
|
pubmed:abstractText |
Objectives of this study were to investigate the effects of prolonged-release melatonin 2 mg (PRM) on sleep and subsequent daytime psychomotor performance in patients aged > or =55 years with primary insomnia, as defined by fourth revision of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association. Patients (N = 40) were treated nightly single-blind with placebo (2 weeks), randomized double-blind to PRM or placebo (3 weeks) followed by withdrawal period (3 weeks). Sleep was assessed by polysomnography, all-night sleep electroencephalography spectral analysis and questionnaires. Psychomotor performance was assessed by the Leeds Psychomotor Test battery. By the end of the double-blind treatment, the PRM group had significantly shorter sleep onset latency (9 min; P = 0.02) compared with the placebo group and scored significantly better in the Critical Flicker Fusion Test (P = 0.008) without negatively affecting sleep structure and architecture. Half of the patients reported substantial improvement in sleep quality at home with PRM compared with 15% with placebo (P = 0.018). No rebound effects were observed during withdrawal. In conclusion, nightly treatment with PRM effectively induced sleep and improved perceived quality of sleep in patients with primary insomnia aged > or =55 years. Daytime psychomotor performance was not impaired and was consistently better with PRM compared with placebo. PRM was well tolerated with no evidence of rebound effects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1473-5857
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
239-49
|
pubmed:meshHeading |
pubmed-meshheading:19584739-Aged,
pubmed-meshheading:19584739-Aged, 80 and over,
pubmed-meshheading:19584739-Delayed-Action Preparations,
pubmed-meshheading:19584739-Double-Blind Method,
pubmed-meshheading:19584739-Electroencephalography,
pubmed-meshheading:19584739-Female,
pubmed-meshheading:19584739-Humans,
pubmed-meshheading:19584739-Male,
pubmed-meshheading:19584739-Melatonin,
pubmed-meshheading:19584739-Middle Aged,
pubmed-meshheading:19584739-Polysomnography,
pubmed-meshheading:19584739-Psychomotor Performance,
pubmed-meshheading:19584739-Questionnaires,
pubmed-meshheading:19584739-Sleep,
pubmed-meshheading:19584739-Sleep Initiation and Maintenance Disorders
|
pubmed:year |
2009
|
pubmed:articleTitle |
The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.
|
pubmed:affiliation |
FORENAP Pharma, Rouffach, France.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|